Management of Opioid-Induced Nausea and Emesis

2003 ◽  
pp. 113-120 ◽  
Author(s):  
R.R. Aparasu ◽  
A. Aparasu
Keyword(s):  
Nausea And Emesis

scholarly journals Antiemetic Prophylaxis for Chemoradiotherapy-induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Heck Squamous Cell Carcinoma: a Prospective Phase Ⅱ Trial

2021 ◽  
Author(s):  
Zekun Wang ◽  
Wenyang Liu ◽  
Jianghu Zhang ◽  
Xuesong Chen ◽  
Jingbo Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Intensity Modulated Radiotherapy ◽  
Complete Response ◽  
High Dose ◽  
Advanced Head ◽  
Free Response ◽  
Nausea And Emesis

Abstract Background There is sparse research reporting effective interventions for preventing nausea and emesis caused by concurrent chemoradiotherapy (CCRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This phase Ⅱ trial was conducted to provide the direct evidence for the current practice of prescribing antiemetic in patients with LA-HNSCC receiving CCRT.Methods Treatment-naïve LA-HNSCC patients received intensity-modulated radiotherapy with concomitant cisplatin 100 mg/m² every 3 weeks for two cycles. All patients were given orally aprepitant 125 mg once on d1, then 80mg once on d2-5; ondansetron 8 mg once on d1; and dexamethasone 12 mg once on d1, then 8mg on d2-5. The primary endpoint was complete response (CR). Pursuant to δ=0.2 and α=0.05, the expected CR rate was 80%. Results A total of 43 patients with LA-HNSCC were enrolled. The median age was 53 years old, and 86.0% were male. All patients received radiotherapy and 86.0% of patients completed both cycles as planned. The overall CR rate was 86.0% (95% CI: 72.1-94.7). The CR rates for cycles 1 and 2 were 88.4% (95% CI: 74.9-96.1) and 89.2% (95% CI: 74.6-97.0). The complete protection rate in the overall phase was 72.1% (95% CI: 56.3-84.7). The emesis-free response and nausea-free response in overall phase were 88.4% (95% CI: 74.9-96.1) and 60.5% (95% CI: 44.4-75.0), respectively. The adverse events related to antiemetics were constipation (65.1%) and hiccups (16.3%), but both were grade 1-2. There was no grade 4 or 5 treatment-related adverse event with antiemetic usage. Conclusion The addition of aprepitant into ondansetron and dexamethasone provided effective protection from nausea and emesis in patients with LA-HNSCC receiving radiotherapy and concomitant high-dose cisplatin chemotherapy. Randomised phase 3 studies are required to further define the potential role of NK1RA in chemoradiotherapy setting.Trial registration: ClinicalTrials.gov, number NCT03572829. Registered 28 June 2018, https://clinicaltrials.gov/ct2/show/NCT03572829?term=NCT03572829&draw=2&rank=1.

scholarly journals Ondansetron and Granisetron in Prophylaxis of Nausea and Emesis Inducedby Cisplatin in Dogs

2005 ◽  
Vol 74 (1) ◽  
pp. 111-116 ◽  
Author(s):  
A. Topal ◽  
M. Kaya ◽  
N. Gül
Keyword(s):  
Nausea And Emesis

A Double-blind, Placebo-controlled Pilot Study Examining the Effectiveness of Intravenous Ondansetron in the Prevention of Postoperative Nausea and Emesis

1993 ◽  
Vol 37 (5) ◽  
pp. 280
Author(s):  
YUNG-FONG SUNG ◽  
BERNARD V. WETCHLER ◽  
DERYCK DUNCALF ◽  
ALANF JOSLYN
Keyword(s):  
Pilot Study ◽  
Postoperative Nausea ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nausea And Emesis

34LBA Fosaprepitant for the prevention of nausea and emesis during five weeks of chemo-radiotherapy: A multinational randomised, placebo-controlled, double-blind trial – the GAND-emesis study

2015 ◽  
Vol 51 ◽  
pp. S727
Author(s):  
C.H. Ruhlmann ◽  
T.B. Christensen ◽  
L.H. Dohn ◽  
M. Paludan ◽  
E. Rannengart ◽  
...  
Keyword(s):  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Nausea And Emesis

Supplemental prophylactic intervention for chemotherapy‐induced nausea and emesis (SPICE) trial: Protocol for a multicentre double‐blind placebo‐controlled randomised trial

2018 ◽  
Vol 77 (1) ◽  
pp. 144-150 ◽  
Author(s):  
Wolfgang Marx ◽  
Alexandra McCarthy ◽  
Skye Marshall ◽  
Megan Crichton ◽  
Alex Molassiotis ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Trial Protocol ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nausea And Emesis

High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.

1985 ◽  
Vol 3 (2) ◽  
pp. 245-251 ◽  
Author(s):  
S B Strum ◽  
J E McDermed ◽  
D F Liponi
Keyword(s):  
Patient Preference ◽  
Nausea And Vomiting ◽  
High Dose ◽  
Chemotherapy Response ◽  
Antiemetic Efficacy ◽  
Study Results ◽  
Nausea And Emesis ◽  
To Receive ◽  
Single Blind ◽  
Crossover Comparison

We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy. Response was determined by using objective and subjective criteria. Thirty patients were randomly assigned to receive MCP alone at a dose of 2 mg/kg IV for three doses or the same dose of MCP plus 20 mg of DXM IV for three doses. Twenty evaluable patients received a second course of cisplatin and were crossed over to the opposite arm. Study results did not show a statistically significant advantage of combination MCP plus DXM over MCP alone using strict objective criteria for antiemetic response. However, patients subjectively preferred MCP plus DXM over MCP alone by nearly a 6:1 ratio, regardless of the randomization sequence. Although the addition of DXM does not appear to objectively improve emetic protection with high-dose MCP, we recommend MCP plus DXM to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy when the use of steroids is not contraindicated, in view of patient preference for the combination.

A double-blind, placebo-controlled pilot study examining the effectiveness of intravenous ondansetron in the prevention of postoperative nausea and emesis

1993 ◽  
Vol 5 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Yung-Fong Sung ◽  
Bernard V. Wetchler ◽  
Deryck Duncalf ◽  
Alan F. Joslyn
Keyword(s):  
Pilot Study ◽  
Postoperative Nausea ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nausea And Emesis

Comparison of Ondansetron with Customary Treatment in the Prophylaxis of Nausea and Emesis Induced by Non-Cisplatin Containing Chemotherapy

1993 ◽  
Vol 32 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Ismo T. Jantunen ◽  
Martti K. Flander ◽  
Mirja I. Heikkinen ◽  
Tapio A. Kuoppala ◽  
Lase Teerenhovi ◽  
...  
Keyword(s):  
Nausea And Emesis
Sign in / Sign up

Export Citation Format

Share Document